PE20001387A1 - Compuestos empleados en el tratamiento de padecimientos inflamatorios - Google Patents

Compuestos empleados en el tratamiento de padecimientos inflamatorios

Info

Publication number
PE20001387A1
PE20001387A1 PE1999001274A PE00127499A PE20001387A1 PE 20001387 A1 PE20001387 A1 PE 20001387A1 PE 1999001274 A PE1999001274 A PE 1999001274A PE 00127499 A PE00127499 A PE 00127499A PE 20001387 A1 PE20001387 A1 PE 20001387A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
phenyl
amino
compound
Prior art date
Application number
PE1999001274A
Other languages
English (en)
Inventor
Duncan Robert Armour
David Brown
Miles Stuart Congreve
Paul Martin Gore
Darren Victor Steven Green
Peter Ward
Torquil Iain Maclean Jack
Steven Philip Keeling
Andrew Mcmurtrie Mason
Karen Morriss
Nigel Grahame Ramsden
Stuart Holman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20001387A1 publication Critical patent/PE20001387A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 Y R2 SON ALQUILO C1-C6, CICLOALQUILO C3-C8, (CH2)e-Ar1, (CH2)eOAr1 O NR1R2 FORMAN PIRROLIDINILO, PIPERIDINILO, PIPERAZINILO, ENTRE OTROS; R3 ES ALQUILO C1-C6-NHC(=NH)NH2, ALQUENILO C2-C6-NHC(=NH)NH2, (CH2)c-2,4-IMIDAZOLIDINODIONA, (CH2)zDIBENZOFURANO, ENTRE OTROS; R4 ES H, ALQUILO C1-C6, ALQUILO C1-C3-CICLOALQUILO C3-C6, (CH2)qAr2, ALQUILO C1-C6-NR12R13, ENTRE OTROS; R5 ES H, JUNTO CON R4 Y C FORMAN CICLOALQUILO C5-C7; R6 ES H, ALQUILO C1-C6, JUNTO A R4 Y C O N FORMAN PIRROLIDINA; R7 ES H, (CH2)wNR12R13, (CH2)uAr2, (CH2)wNR12-COALQUILO C1-C6; R8, R9, R16 SON H, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; R12, R13 SON H, ALQUILO C1-C6; Ar1 ES FENILO, HETEROCICLO 5-6 MIEMBROS CON 1-3 O, N, S; Ar2 ES FENILO; c, z SON 0-2; u ES 1-2; e Y w SON 1-3. UN COMPUESTO PREFERIDO ES ACIDO (2S)-2-[((2S)-2-{[2-(2-BENZOILFENOXI)ACETIL]AMINO}-4-METILPENTANOIL)AMINO]-3-{4-[({4-[(2-FENILACETIL)AMINO]-1-PIPERIDINIL}CARBONIL)OXI}FENIL}PROPIONICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION, A COMPUESTOS INTERMEDIOS Y A UNA COMPOSICION QUE COMPRENDE ADEMAS A UN AGONISTA DEL RECEPTOR ADRENERGICO ß2. EL COMPUESTO DE FORMULA I ES UN ANTAGONISTA DE O4-INTEGRINA Y PUEDEN SER UTILES COMO AGENTES ANTIINFLAMATORIOS
PE1999001274A 1998-12-18 1999-12-16 Compuestos empleados en el tratamiento de padecimientos inflamatorios PE20001387A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9828074.6A GB9828074D0 (en) 1998-12-18 1998-12-18 Therapeutically useful compounds

Publications (1)

Publication Number Publication Date
PE20001387A1 true PE20001387A1 (es) 2000-12-22

Family

ID=10844608

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001274A PE20001387A1 (es) 1998-12-18 1999-12-16 Compuestos empleados en el tratamiento de padecimientos inflamatorios

Country Status (26)

Country Link
US (1) US6867192B1 (es)
EP (1) EP1140837B1 (es)
JP (1) JP4431282B2 (es)
KR (1) KR20010101258A (es)
CN (1) CN1330637A (es)
AR (1) AR023727A1 (es)
AT (1) ATE273954T1 (es)
AU (1) AU760169B2 (es)
BR (1) BR9916282A (es)
CA (1) CA2355630A1 (es)
CO (1) CO5170533A1 (es)
CZ (1) CZ20012209A3 (es)
DE (1) DE69919580T2 (es)
ES (1) ES2226488T3 (es)
GB (1) GB9828074D0 (es)
GT (1) GT199900217A (es)
HK (1) HK1038744A1 (es)
HU (1) HUP0104867A3 (es)
IL (1) IL142908A0 (es)
NO (1) NO20012995L (es)
NZ (1) NZ511478A (es)
PE (1) PE20001387A1 (es)
PL (1) PL348059A1 (es)
TR (1) TR200101709T2 (es)
WO (1) WO2000037444A1 (es)
ZA (1) ZA200103948B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396087A1 (en) 1999-12-28 2001-07-19 Louis Stanley Chupak Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
GB0014869D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014947D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014851D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014881D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0014849D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0014883D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0127423D0 (en) * 2001-11-15 2002-01-09 Glaxo Group Ltd Process
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
EP1633731A2 (en) 2003-05-20 2006-03-15 Genentech, Inc. Thiocarbamate inhibitors of alpha-4 integrins
CN1993143A (zh) 2004-06-04 2007-07-04 健泰科生物技术公司 用于治疗多发性硬化的方法
US9082353B2 (en) 2010-01-05 2015-07-14 Pixtronix, Inc. Circuits for controlling display apparatus
US7999994B2 (en) 2005-02-23 2011-08-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US9261694B2 (en) 2005-02-23 2016-02-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US8482496B2 (en) 2006-01-06 2013-07-09 Pixtronix, Inc. Circuits for controlling MEMS display apparatus on a transparent substrate
US8519945B2 (en) 2006-01-06 2013-08-27 Pixtronix, Inc. Circuits for controlling display apparatus
US8310442B2 (en) 2005-02-23 2012-11-13 Pixtronix, Inc. Circuits for controlling display apparatus
US9158106B2 (en) 2005-02-23 2015-10-13 Pixtronix, Inc. Display methods and apparatus
US9229222B2 (en) 2005-02-23 2016-01-05 Pixtronix, Inc. Alignment methods in fluid-filled MEMS displays
US20070205969A1 (en) 2005-02-23 2007-09-06 Pixtronix, Incorporated Direct-view MEMS display devices and methods for generating images thereon
US7742016B2 (en) 2005-02-23 2010-06-22 Pixtronix, Incorporated Display methods and apparatus
US8159428B2 (en) 2005-02-23 2012-04-17 Pixtronix, Inc. Display methods and apparatus
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US8526096B2 (en) 2006-02-23 2013-09-03 Pixtronix, Inc. Mechanical light modulators with stressed beams
US9176318B2 (en) * 2007-05-18 2015-11-03 Pixtronix, Inc. Methods for manufacturing fluid-filled MEMS displays
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
US8169679B2 (en) 2008-10-27 2012-05-01 Pixtronix, Inc. MEMS anchors
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
KR20120139854A (ko) 2010-02-02 2012-12-27 픽스트로닉스 인코포레이티드 디스플레이 장치를 제어하기 위한 회로
CN102834763B (zh) 2010-02-02 2015-07-22 皮克斯特罗尼克斯公司 用于制造填充冷密封流体的显示装置的方法
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
MX2014009043A (es) 2012-01-31 2014-10-14 Genentech Inc Anticuerpos anti-ige y sus metodos de uso.
US9134552B2 (en) 2013-03-13 2015-09-15 Pixtronix, Inc. Display apparatus with narrow gap electrostatic actuators
CN106659697B (zh) * 2014-05-30 2022-03-29 斯菲叶尔制药私有公司 作为抗结核剂的化合物
KR102440162B1 (ko) 2015-07-08 2022-09-02 악세로비젼, 인크. 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물
WO2017062682A2 (en) 2015-10-06 2017-04-13 Genentech, Inc. Method for treating multiple sclerosis
AU2017273857B2 (en) * 2016-06-01 2021-08-19 Athira Pharma, Inc. Compounds
CN109722455B (zh) * 2017-10-31 2022-03-11 中国科学院天津工业生物技术研究所 微生物发酵生产谷内酯的方法、工程菌及应用
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
CR20210213A (es) 2018-10-30 2021-06-24 Gilead Sciences Inc Derivados de quinolina como inhibidores de la integrina alfa4beta7
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN116670116A (zh) * 2020-10-21 2023-08-29 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593858A1 (de) * 1967-03-02 1970-10-29 Hoechst Ag Verfahren zur Herstellung tyrosinhaltiger Peptide und deren Derivaten
US4105602A (en) 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
CA2291762A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
JP2002512625A (ja) 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
WO1998053818A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
DE69820614T2 (de) 1997-05-30 2004-09-30 Celltech Therapeutics Ltd., Slough Entzündungshemmende tyrosin-derivate

Also Published As

Publication number Publication date
ATE273954T1 (de) 2004-09-15
HK1038744A1 (zh) 2002-03-28
NZ511478A (en) 2003-08-29
KR20010101258A (ko) 2001-11-14
AU3039100A (en) 2000-07-12
TR200101709T2 (tr) 2001-12-21
EP1140837B1 (en) 2004-08-18
IL142908A0 (en) 2002-04-21
GT199900217A (es) 2001-06-09
US6867192B1 (en) 2005-03-15
BR9916282A (pt) 2001-10-02
DE69919580D1 (de) 2004-09-23
DE69919580T2 (de) 2005-09-01
AU760169B2 (en) 2003-05-08
EP1140837A1 (en) 2001-10-10
HUP0104867A3 (en) 2002-06-28
HUP0104867A2 (hu) 2002-04-29
CZ20012209A3 (cs) 2001-09-12
PL348059A1 (en) 2002-05-06
ES2226488T3 (es) 2005-03-16
CO5170533A1 (es) 2002-06-27
JP4431282B2 (ja) 2010-03-10
AR023727A1 (es) 2002-09-04
NO20012995L (no) 2001-08-15
WO2000037444A1 (en) 2000-06-29
JP2002533326A (ja) 2002-10-08
CN1330637A (zh) 2002-01-09
CA2355630A1 (en) 2000-06-29
NO20012995D0 (no) 2001-06-15
GB9828074D0 (en) 1999-02-17
ZA200103948B (en) 2002-11-15

Similar Documents

Publication Publication Date Title
PE20001387A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
ES2572980T3 (es) Combinación de inhibidores de la proteasa del VHC con un tensioactivo
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
PE20040775A1 (es) DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2
PE20040780A1 (es) Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion
PE20030258A1 (es) Derivados de dolastatina con actividad antitumoral
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
PE20021004A1 (es) Derivados de piperidina como inhibidores de la ccr5
PE20061163A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos
PE20070004A1 (es) Imidazoquinolinas como inhibidores de quinasa de lipido
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
ECSP045317A (es) Piridinoilpiperidinas como agonistas de 5-ht1f
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
PE20040898A1 (es) Nuevos compuestos derivados de pirimidina
PE20061367A1 (es) Nuevos derivados del fluoreno y composiciones que los contienen
AR035710A1 (es) Compuesto derivado de beta-aminoacidos ciclicos, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento para el tratamiento de una enfermedad mediada por mmps, tnf, agrecanasa y combinaciones de los mismos
PE20020220A1 (es) Compuestos de nitrilo de dipeptido como inhibidores de catepsina k
PE20020917A1 (es) Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato
PE20080072A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
PE20061049A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida como antagonistas del receptor de vanilloides tipo 1 (vr1)
UY28101A1 (es) Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer
MEP22508A (en) Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed